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sor the ACC.06 Scientific Sessions, the Program Commit-
ee received 736 submissions in the area of heart failure
HF), 244 of which were accepted for presentation. Al-
hough there were a limited number of large HF clinical
rials, HF and cardiac function topics were well represented
n various core curriculum sessions, symposia, and interac-
ive sessions.
HE UNLOAD TRIAL
n estimated 90% of HF hospitalizations are attributable to
olume overload, and hypervolemia contributes to HF
rogression, mortality, and high rehospitalization rates.
ltrafiltration is a novel therapy for HF and may be an
lternative to aggressive intravenous (IV) diuretic therapy. A
ate-breaking clinical trial featured the results of the Ultra-
ltration Versus Intravenous Diuretics for Patients Hospi-
alized for Acute Decompensated Heart Failure (UNLOAD)
rial. Costanzo et al. for the UNLOAD trial investigators
1) hypothesized that ultrafiltration would be superior to
ggressive IV diuretic therapy for reducing volume overload
n hypervolemic HF patients and would be associated with
ustained clinical benefits while maintaining a safety profile
imilar to that of IV diuretics.
In this prospective, randomized, multicenter trial, the
ffects of early venovenous ultrafiltration alone (n  100)
ersus IV diuretics alone (n  100) were compared to assess
heir effects on weight loss, symptoms, and rehospitalization
ates of hypervolemic HF patients. The two primary end
oints were weight loss and dyspnea score at 48 h after
andomization.
Patients were included if they were hospitalized with
cute decompensated HF with evidence of volume overload
nd at least two of the following: peripheral edema 2;
ugular venous distension 7 cm; radiographic pulmonary
dema or pleural effusion; enlarged liver or ascites; and
ulmonary rales, paroxysmal nocturnal dyspnea, or orthop-
ea. Randomization occurred within 24 h of hospitalization.
Patients participating in the UNLOAD trial did not
ecessarily have low ejection fractions, which was evident by
he medications they were receiving at baseline; only 49% of
atients were on angiotensin-converting enzyme inhibitors
nd only about 65% were on beta-blockers. At study entry,
atients were taking a fairly substantial dose of furosemide
ultrafiltration group 129 mg/m vs. standard care 119
g/m).
From the *Heart Failure and Cardiac Transplant Program, University of Cincin-a
ati, Cincinnati, Ohio; †Cleveland Clinic, Cleveland, Ohio; and the ‡Duke Univer-
ity Medical Center, Duke Clinical Research Institute, Durham, North Carolina.At 48 h, the ultrafiltration-treated patients experienced
ignificantly greater weight loss (5.0 kg vs. 3.1 kg, p 
.001); however, because the trial was not blinded, standard
are was administered by physicians individually. The other
rimary end point, dyspnea score, was not statistically
ignificant between the arms (6.4 vs. 6.1, p  0.35). The
8-h time point selected for comparison may have been long
nough that both patient groups were feeling substantially
etter at that time despite the treatment arm to which they
ere randomized.
There was no difference in deaths between the two
roups, most of which were attributable to HF. An impor-
ant parameter to consider, however, is resource use for HF
t 90 days (Table 1). Patients in the ultrafiltration-treated
roup required significantly fewer rehospitalizations, and
hose who were rehospitalized spent fewer days in hospital.
he patients who received ultrafiltration also experienced
ignificantly fewer unscheduled clinic visits plus emergency
epartment visits.
The trial investigators concluded that early ultrafiltration
roduced greater weight loss than IV diuretics at 48 h,
ithout differences in renal function between the two
roups. A question that could be raised is whether the same
ffect could be achieved with more aggressive diuretic
dministration; likely another larger clinical trial would be
eeded to answer this. An early ultrafiltration strategy did
educe resource use based on 90-day HF rehospitalization
ates and in-hospital days. Another issue is whether symp-
oms and biomarkers of congestion are sufficiently sensitive
o detect the differences in volume loss produced by the two
herapies. Although HF patients lost more weight, there
as not a difference in the dyspnea score. This suggests that
hange in dyspnea may not be a valid end point for acute
F trials.
ARVEDILOL IN CHILDREN
n a landmark trial in the pediatric HF population, Shaddy
t al. (2) conducted a multicenter, randomized, placebo-
ontrolled trial with 161 patients randomized 1:1:1 to
lacebo, low-dose (target dose 0.2 mg/kg/dose) carvedilol,
r high-dose (target dose 0.4 mg/kg/dose) carvedilol, all
iven twice daily. This was the first study to prospectively
haracterize the pediatric HF population in the setting of a
linded, controlled, randomized trial.
Because pediatric patients experience HF dependent on
he systemic ventricle and their congenital anatomy, the
ubjects were stratified based on the echocardiographic
ppearance of the systemic ventricle (either left ventricular
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June 6, 2006:D18–22 ACC 2006 Annual Session HighlightsLV] or non-LV). Both of these patient types were included
n the trial, and doses were titrated upward per protocol
uring biweekly office visits. Patients were enrolled up to 17
ears of age, with chronic symptomatic HF caused by
ystemic ventricular systolic dysfunction. Older children had
ew York Heart Association (NYHA) functional class II to
V disease, with younger children assessed based on the
oss classification for HF class II through IV. Left ventric-
lar ejection fraction (LVEF) was 40% in patients with
ystemic LV dysfunction, or there was qualitative evidence
f a dilated ventricle with systemic ventricular systolic
ysfunction in patients with non-LV HF. The trial’s pri-
ary end point was HF outcome at eight months (based on
vidence of worsening, improvement, or no change) and
efined by the composite of death, hospitalization, or
iscontinuation for worsening HF, NYHA or Ross classi-
cation, and/or global assessment score.
Of the 161 children enrolled at 26 centers in the U.S.
ver a period of 4 years, 52% were female and systemic
entricular morphology was LV-related in 78% of all pa-
ients. Most were in NYHA functional class II or III (class
I 71%; class III 27%), with ages ranging from 3 months to
able 1. Outcomes at 48 h and 90 Days in the UNLOAD
rial
Ultrafiltration
Standard
Care
p
Value
8 h
Weight loss (kg) 5.0 3.1 0.001
Change in dyspnea score 6.4 6.1 0.35
0 days
Patients rehospitalized 18% 32% 0.022
Rehospitalizations/patient 0.22 0.46 0.037
Days rehospitalized 123 330 0.022
Abbreviations and Acronyms
A-HeFT  African-American Heart Failure
Trial
AVP  arginine vasopressin
GRAHF  Genetic Risk Assessment in Heart
Failure trial
HF  heart failure
IMPACT-HF  Initiation Management
Presdischarge: Process for
Assessment of Carvedilol Therapy
in Heart failure trial
IV  intravenous
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
OPTIMIZE-HF  Organized Program to Initiate Life-
Saving Treatment in Hospitalized
Patients with Heart Failure registry
UNLOAD  Ultrafiltration Versus Intravenous
Diuretics for Patients Hospitalized
for Acute Decompensated Heart
Failure trialpMortality 9.6% 11.6% NS7 years (median 3 years). Nearly one-half (45%) were 2
ears of age. In this study, median LVEF was only 26%,
ith a median B-type natriuretic peptide level of 111 pg/ml,
hich is low for a symptomatic HF population.
This primary end point was not met; a similar percentage
f patients in both the placebo and the combined carvedilol
roups showed improvement (Fig. 1). There was a trend
avoring carvedilol in terms of all-cause mortality (hazard
atio 0.68; p  0.53) and the combination of all-cause
ortality and HF hospitalization (hazard ratio 0.76; p 
.55). The fact that these differences did not reach statistical
ignificance may have been attributable to the small number
f patients enrolled in the trial.
Although patients in each of the carvedilol groups had
igher ejection fractions at follow-up (each p  0.001 vs.
creening), patients in the placebo group unexpectedly
xperienced a similar significant improvement in LVEF, so
omparison among patients was not statistically significant,
lthough the carvedilol patients ended up with higher
VEFs than the placebo patients.
This study did not detect a treatment effect of carvedilol;
owever, because of the substantially large placebo improve-
ent response, a larger study would likely be necessary to
how a difference. The high level of improvement seen in
he placebo group, as well as the potential interaction with
he systemic ventricular anatomy, should be taken into
onsideration for future clinical trials, although conducting
placebo-controlled beta-blocker trial in any age group is
ifficult today. Remarkably this is the first study to prospec-
ively characterize the pediatric HF population in the
etting of a blinded, controlled, and randomized trial.
ARVEDILOL USE AT DISCHARGE
atients hospitalized with HF are at high risk for mortality
nd rehospitalization, especially in the first 60 to 90 days
fter discharge. Whether carvedilol use at the time of
ospital discharge influences early survival and other clinical
utcomes has not been well studied. The Initiation Man-
gement Predischarge: Process for Assessment of Carvedilol
herapy in Heart Failure (IMPACT-HF) trial assessed the
redischarge initiation of carvedilol on subsequent treat-
ent rates (n  363) (3). Treatment rates were improved
nd therapy was safe, but this trial was not adequately
owered to assess outcomes. Whether carvedilol use at the
ime of hospital discharge influences early survival and other
linical outcomes has not been well studied.
Fonarow et al. (4) examined the Organized Program to
nitiate Life-Saving Treatment in Hospitalized Patients
ith Heart Failure (OPTIMIZE-HF) registry to investi-
ate the relationship between discharge use of carvedilol and
arly clinical outcomes among patients hospitalized with
F. The investigators tested the association with clinical
utcomes of carvedilol use at hospital discharge in eligible
atients with LV systolic dysfunction versus those eligible
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ACC 2006 Annual Session Highlights June 6, 2006:D18–22ut who received no beta-blocker at discharge. The
PTIMIZE-HF is a registry/performance improvement
rogram for patients hospitalized with HF.
The mean patient age was 69.5 years; 63% were male,
5% were Caucasian, and 34% had ischemic etiology. Of
he 2,720 patients with LV systolic dysfunction, 87.2% (n
,373) were eligible to receive a beta-blocker at discharge.
arvedilol was prescribed at discharge in 1,145 patients,
ith 94.3% remaining on therapy during follow-up. In
ligible patients not discharged on any beta-blocker (n 
61), only 30.4% were started on beta-blocker after
ischarge. Carvedilol use was associated with signifi-
antly decreased risk for death (Fig. 2) (odds ratio 0.46
95% confidence interval 0.30 to 0.73], p  0.0006; and
eath or rehospitalization, odds ratio 0.72 [95% confi-
ence interval 0.53 to 0.94], p  0.0175) without early
azard for recurrent decompensation.
Limitations of the study include the fact that the
PTIMIZE-HF registry was not a prospective randomized
rial and, despite covariate adjustment and propensity
atching, other measured and unmeasured factors may have
nfluenced outcomes. Contraindications and intolerance
%
Placebo
(n=54)
55.6
2
14.8
0
10
20
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40
50
60
igure 1. Heart failure composite outcome (death, hospitalization, or disco
ssessment score at eight months) (primary end point), Pediatric Carved
mproved; yellow bars  unchanged; green bars  worsened.Figure 2. Survival after heart failure hospital dere as documented in the medical record; a proportion of
atients reported to be eligible for treatment but not treated
ay have had contraindications or intolerances that were
resent but not documented. Finally, follow-up was limited
o the first 60 to 90 days after discharge.
The investigators conclude that carvedilol use at the time of
F hospital discharge is associated with an early survival
enefit in patients with systolic HF. Carvedilol use at the time
f HF hospital discharge is also associated with a reduction in
eath or rehospitalization in the first 60 to 90 days after
ischarge. In this large, representative HF population, carve-
ilol treatment at the time of hospital discharge showed no
vidence of an increased early hazard for recurrent decompen-
ation. Carvedilol treatment at the time of hospital discharge
eems to be well tolerated (based on the high percentage of
atients who remained on treatment) and associated with
mproved treatment rates at 60 to 90 days of follow-up.
ONIVAPTAN IN HYPONATREMIA
nappropriate secretion of arginine vasopressin (AVP) often
esults in hyponatremia, defined as a serum sodium concen-
Carvedilol
Combined
(n=103)
56.3
24.3
19.4
ation for worsening heart failure, heart failure classification, and/or global
udy Group. p  0.74 carvedilol combined versus placebo. Blue bars 9.6
ntinu
ilol Stischarge. Reprinted with permission (4).
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June 6, 2006:D18–22 ACC 2006 Annual Session Highlightsration 135 mEq/l (5,6). This is common in patients
ith HF and is associated with increased morbidity and
ortality (7). Ghali et al. (8) assessed use of the novel AVP
ntagonist conivaptan in HF patients with either euvolemic
r hypovolemic hyponatremia. In previous studies,
onivaptan has been shown to produce aquaresis, which is
he electrolyte-sparing excretion of water, by blocking
VP V2 receptors in the renal collecting ducts (9).
onivaptan also blocks V1A receptors, with the overall
esult of improvement in hyponatremia.
In this trial, mean baseline sodium was very low: about
24 mEq/l across the various patient groups. The trial
ncluded 57 patients with HF as well as another 57 patients
ithout HF but with other etiologies of hyponatremia.
ubjects were randomized to IV conivaptan 40 mg/day or
0 mg/day or placebo for 14 days in the hospital.
Whether patients did or did not have HF, both dose
evels of conivaptan produced a significant mean change
rom baseline in serum sodium versus placebo. Moreover,
he percentage of patients who had a 6 mEq/l equivalent
ncrease in serum sodium or had a normal serum sodium at
he end of treatment was impressive: 87.5% of HF patients
reated with high-dose conivaptan (p  0.0025 vs. placebo)
Fig. 3).
Drug-related adverse events trended higher with active
herapy, although not necessarily for the most serious
dverse events; however, that may be a concern for other
rugs in this category. Most of the adverse events related to
enal failure occurred in the HF patients.
ENOMICS IN HF
n exciting new area of study, genomics in HF, received
ttention from several investigators, including McNamara et al.
10) in a substudy of the African-American Heart Failure Trial
A-HeFT). The Genetic Risk Assessment in Heart Failure
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40 mg/d
(n=10)
CN
80 m
(n=
*
11.1
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60.0
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100
igure 3. Use percentage of patients showing a 6 mEq/l increase in serum
reatment. *p 0.0359; †p 0.0025; ‡p 0.032; §p 0.0023 vs. placebo fromGRAHF) trial is a prospectively defined genetic analysis of-HeFT study patients. It was designed to prospectively
dentify specific, shared biomarkers within patient cohorts to
elineate subsets of patients who may benefit from the com-
ination of isosorbide dinitrate and hydralazine.
In some individuals, a polymorphism exists in the promoter
egion of the aldosterone synthase gene (CYP11B2) at the
344C position (C/T). Investigators discovered a racial dif-
erence in the frequency of these C/T variations. In the
RAHF trial, for example, 62% of African-American patients
ith HF possessed the genotype TT, whereas 38% were either
C or CC. Comparatively, in an earlier study (Genetic Risk
ssessment of Cardiac Events [GRACE]), about one-third of
aucasian patients with HF possessed the TT variation.
resence of the 344 C allele has been linked to increased
ldosterone production, and in the GRAHF trial, these pa-
ients had the greatest risk of death or hospitalization for HF
event-free survival).
The A-HeFT study patients with the TT variation were
ound to have the lowest risk for death or hospitalization for
F (10). In addition, patients with the TT variation receiving
sosorbide dinitrate and hydralazine had statistically better
rimary composite scores compared with patients who received
lacebo, driven primarily by improvement in functional status.
hus, the investigators concluded that the promoter genotype
s linked to higher aldosterone levels as well as to poorer
vent-free survival in African-American patients with HF. The
ossibilities in terms of analyzing genetic responses and phar-
acogenomic responses to HF therapies are creating new
orizons in our understanding and treatment of HF.
Among the overall conclusions from these HF studies:
Ultrafiltration is a modality that effectively alleviates
volume overload in acutely decompensated HF patients
and is safe.
Ultrafiltration may decrease readmissions more than IV
Placebo
(n=20)
CNV
40 mg/d
(n=19)
CNV
80 mg/d
(n=18)
Patients
without HF
‡
25.0
88.9
73.7
ium or normal serum sodium at the end of intravenous conivaptan (CNV)
hran-Mantel-Haenszel test. Adapted with permission (8). HF heart failure.V
g/d
8)
†
.5
soddiuretic use alone.
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ACC 2006 Annual Session Highlights June 6, 2006:D18–22Pediatric HF trials are difficult to conduct for many
reasons.
Carvedilol did not show a benefit in pediatric HF
patients; however, trends were in favor of carvedilol
therapy. The study was underpowered to detect a statis-
tical difference, and the placebo group improved more
than expected.
Carvedilol use at the time of HF hospital discharge may
be associated with an early survival benefit in patients
with systolic HF and seems to be well tolerated.
Conivaptan significantly increases serum sodium in both
HF patients and non-HF patients with hyponatremia.
Finally, the field of genomics in HF continues to evolve.
eprint requests and correspondence: Dr. Lynne E. Wagoner,
ivision of Cardiology, University of Cincinnati, 231 Albert Sabin
ay, Cincinnati, Ohio 45267-0542. E-mail: wagonele@ucmail.
c.edu.
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